Does debulking surgery improve survival in biologically aggressive ovarian carcinoma?

Gynecologic Oncology

Volumn 67, Issue 2, 1997, Pages 208-214

  Le, T ^a   Krepart, G V ^b   Lotocki, R J ^b   Heywood, M S ^b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER INVASION; CANCER SURGERY; CANCER SURVIVAL; EPITHELIUM CELL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

EID: 0031281766     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1997.4839     Document Type: Article

References (18)

1. American Cancer Society, 1996, Cancer facts and figures - 1996, American Cancer Society.
2. Griffiths C T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr. 42:1975;101-104.
3. Hacker N F, Berek J S, Lagasse L D, Niebrig R K, Elashoff R M. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol. 61:1983;413-420.
4. Delgado G, Oram D H, Petrilli E S. Stage 3 ovarian cancer: The role of maximal surgical cytoreduction. Gynecol Oncol. 18:1984;293.
5. Allen D G, Heintz A P, Touw F W. A meta-analysis of residual disease and survival in stage 3 and 4 carcinoma of the ovary. Eur J Gynecol Oncol. 16:1995;349-356.
6. Hoskin W J, Bundy B N, Thigpen T J, Omura G A. The influence of cytoreductive surgery on recurrence-free interval and survival in small volume stage 3 epithelial ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol. 47:1992;159-166.
7. Kaplan E L, Meier P. Non parametric estimation from incomplete observation. J Am Stat Assoc. 53:1958;457-481.
8. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 50:1966;163-170.
9. Rubin S C. Surgery for ovarian cancer. Hematol Oncol Clin North Am. 6:1992;851-865.
10. Makar A P, Baekelandt M, Trope C G, Kristensen G B. The prognostic significance of residual disease, FIGO substage, tumour histology, and grade in patients with FIGO stage 3 ovarian cancer. Gynecol Oncol. 56:1995;175-180.
11. Farias-Eisner R, Teng F, Oliveira M, Leuchter R, Karlan B, Lagasse L D, Berek J S. The influence of tumor grade, distribution, and extent of carcinomatosis in minimal residual stage 3 epithelial ovarian cancer after optimal primary cytoreductive surgery. Gynecol Oncol. 55:1994;108-110.
12. Van der Berg M EJ, Van Lent M. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med. 332:1995;629.
13. Goldie J H, Coldman A J. A mathematical model for relating the drug sensitivity of tumours to their spontaneous mutation rate. Cancer Treat Rep. 63:1979;1727-1733.
14. Goldie J H, Coldman A J. The genetic origin of drug resistance in neoplasms: Implications for systemic therapy. Cancer Res. 44:1984;3643-3653.
15. Chambers J T, Chambers S K, Voynick I M, Schwartz P E. Neoadjuvant chemotherapy in stage X ovarian carcinoma. Gynecol Oncol. 37:1990;327-331.
16. Schwartz P E, Chambers J T, Makuch R. Neoadjuvant chemotherapy for advanced ovarian cancer. Gynecol Oncol. 53:1994;33-37.
17. Surwitt E, Childers J, Atlas I, Nour M, Hatch K, Hallum A, Alberts D. Neoadjuvant chemotherapy for advanced ovarian cancer. Int J Gynecol Cancer. 6:1996;356-361.
18. P, E, Schartz, J, T, Chambers, E, I, Kohorn, T, J, Rutherford, W, Schubert, D, Zelterman, September 16, 1996, Neoadjuvant chemotherapy for advanced ovarian cancer: Long term survival, 31.